评估阿巴西普治疗激素难治性慢性移植物抗宿主病的2期临床试验
该2期研究评估阿巴西普治疗异基因移植后激素难治性慢性移植物抗宿主病的疗效,36例中21例有效,总缓解率58%,均为部分缓解;药物耐受良好,严重感染并发症少;免疫相关研究显示治疗后白细胞介素-1α、白细胞介素-21、肿瘤坏死因子α及CD4+ T细胞程序性死亡蛋白1表达下降。
要点
- 激素难治性慢性移植物抗宿主病患者中,阿巴西普总缓解率为58%(21/36),所有缓解者均为部分缓解。
- 阿巴西普耐受性良好,严重感染并发症少。
- 治疗后所有患者白细胞介素-1α、白细胞介素-21、肿瘤坏死因子α及CD4+ T细胞程序性死亡蛋白1表达下降。
核心结论
- 阿巴西普是治疗慢性移植物抗宿主病有前景的治疗策略。
研究设计与样本
- 2期研究,评估阿巴西普治疗激素难治性慢性移植物抗宿主病的疗效,共36例患者。
主要发现
- 总缓解率为58%,见于36例患者中的21例,所有缓解者均达到部分缓解。
- 阿巴西普耐受性良好,严重感染并发症少。
- 免疫相关研究显示,所有患者接受阿巴西普治疗后白细胞介素-1α、白细胞介素-21和肿瘤坏死因子α下降,CD4+ T细胞程序性死亡蛋白1表达下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Steroid-refractory chronic graft-versus-host disease (cGVHD) after allogeneic transplant remains a significant cause of morbidity and mortality. Abatacept is a selective costimulation modulator, used for the treatment of rheumatologic diseases, and was recently the first drug to be approved by the US Food and Drug Administration for the prophylaxis of acute graft-versus-host disease. We conducted a phase 2 study to evaluate the efficacy of abatacept in steroid-refractory cGVHD. The overall response rate was 58%, seen in 21 out of 36 patients, with all responders achieving a partial response. Abatacept was well tolerated with few serious infectious complications. Immune correlative studies showed a decrease in interleukin -1α (IL-1α), IL-21, and tumor necrosis factor α as well as decreased programmed cell death protein 1 expression by CD4+ T cells in all patients after treatment with abatacept, demonstrating the effect of this drug on the immune microenvironment. The results demonstrate that abatacept is a promising therapeutic strategy for the treatment of cGVHD. This trial was registered at www.clinicaltrials.gov as #NCT01954979.
引用
- Koshy AG, Kim HT, Liegel J, et al. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2023. PMID: 36862975. doi:10.1182/blood.2022019107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。